A case study highlights the delayed diagnosis of primary cutaneous histoplasmosis in a patient undergoing tumor necrosis factor alpha inhibitor therapy. This underscores the need for heightened awareness of rare infections in immunocompromised patients.
delayed diagnosis of primary cutaneous histoplasmosis in a patient receiving tumour necrosis factor alpha inhibitor therapy
Original title: “Delayed diagnosis of primary cutaneous histoplasmosis in a patient receiving tumour necrosis factor alpha inhibitor therapy.”